Literature DB >> 26211111

High pre-pregnancy body mass index and the risk of poor obstetrics outcomes among Asian women using BMI criteria for Asians by World Health Organization Western Pacific Region (WPRO): a large cohort study.

Charintip Somprasit, Chamnan Tanprasertkul, Thawanwong Rattanasiri, Piyamas Saksiriwutth, Jamras Wongkum, Ekachai Kovavisarach, Khwanjira Jongfueangparinya, Pritsana Panichakul, Juthawadee Wuthiwong.   

Abstract

OBJECTIVE: To evaluate the effects of high pre-pregnancy body mass index (BMI) on the risk ofpoor obstetric outcomes among Asian women using BMI criteria by Regional Office for the Western Pacific Region of WHO (WPRO). MATERIAL AND
METHOD: The present study was a retrospective cohort. Subjects of live birth singletons who had full term delivered atfour tertiary care centers, teaching university hospitals between January and December 2012 were enrolled. All pregnant women with pre-pregnancy BMI 18.5 kg/m2 or over were recruited and categorized into two groups, normal BMI and high BMI Level of BMI at 18.5-22.9 kg/m2 was defined normal BMI, and level at or over than 23 kg/M2 was defined as high BMI, respectively. The association between high pre-pregnancy BMI and poor adverse pregnancy outcomes were evaluated.
RESULTS: Two thousands seven hundred and thirty-three pregnant women were recruited. Normal and high pre-pregnancy BMI women were 1,840 and 893, respectively. The average age was 2 7.81 +/- 5.67 and 29.48 +/- 13.03 years old respectively. Most ofsubject were primigravida. Mean BMI of normal group and high BMI group were 20.2 7 +/- 1.42 and 26.66 +/- 3.45 kg/ m2, respectively. In multivariate analysis, high pre-pregnancy BMI pregnant women have significantly higher adjusted risk ratio for gestational diabetes mellitus and preeclampsia, induction of labor prolong second stage of labor, including, caesarean delivery or obstetrics procedures (RR 1.54, 95% CI 1.30-1.84, RR 1.17, 95% CI 1. 12-1.23, RR 1.41, 95% CI 1. 04- 1.90, RR 1.28, 95% CI 1.11-1.48 and RR 1.17, 95% CI 1.05-1.27, respectively). In addition, the adjusted risk ratio of postpartum hemorrhage and neonatal macrosomia were significantly increased (RR 1.86, 95% CI 1.01-3.43 and RR 1.46, 95% CI 1.28-1.65, respectively).
CONCLUSION: This evidence strongly suggested that high pre-pregnancy BMI using WPRO criteria increased the risk of pregnancy complications and adverse pregnancy outcomes. This study was one of the largest studies among Asian populations.

Entities:  

Mesh:

Year:  2015        PMID: 26211111

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  5 in total

1.  Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers.

Authors:  Qing-Xia Li; Dong-Jian Shi; Li-Xia Zhang; Dong-Miao Wang; Jing Zhao; Tao Wang; Xin-Na Deng; Xiao-Yan Fan
Journal:  J Int Med Res       Date:  2019-03-07       Impact factor: 1.671

2.  The study of metabolic improvement by nutritional intervention controlling endogenous GIP (Mini Egg study): a randomized, cross-over study.

Authors:  Naoki Sakane; Noriko Osaki; Hideto Takase; Junko Suzuki; Chika Suzukamo; Shinsuke Nirengi; Akiko Suganuma; Akira Shimotoyodome
Journal:  Nutr J       Date:  2019-09-02       Impact factor: 3.271

Review 3.  Gestational Diabetes Mellitus in Southeast Asia: A Scoping Review.

Authors:  Thubasni Kunasegaran; Vinod R M T Balasubramaniam; Valliammai Jayanthi Thirunavuk Arasoo; Uma Devi Palanisamy; Amutha Ramadas
Journal:  Int J Environ Res Public Health       Date:  2021-01-31       Impact factor: 3.390

4.  Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes and preeclampsia.

Authors:  Congcong Liu; Jinsong Gao; Juntao Liu; Xietong Wang; Jing He; Jingxia Sun; Xiaowei Liu; Shixiu Liao
Journal:  Ann Transl Med       Date:  2020-12

5.  Association of pre-pregnancy body mass index and gestational weight gain with labor stage.

Authors:  Li Zhou; Hui-Xia Yang; Rui-Fen Zhao; Wei-Yuan Zhang
Journal:  Chin Med J (Engl)       Date:  2019-02       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.